Abstract

We report the G protein-first mechanism for activation of G protein-coupled receptors (GPCR) for the three closest subtypes of the opioid receptors (OR), μOR, κOR and δOR. We find that they couple to the inactive Gi protein-bound guanosine diphosphate (GDP) prior to agonist binding. The inactive Gi protein forms anchors to the intracellular loops of the inactive apo-μOR, apo-κOR and apo-δOR, inducing opening of the cytoplasmic region to form a pre-activated state that holds Gi protein in place until agonist binds. Then, agonist binds to μOR, κOR and δOR already complexed with Gi protein, to trigger the Gαi to open up the tightly coupled GDP binding site, making GDP accessible for GTP exchange, an essential step for Gi signalling. We show that the agonist alone cannot open the intracellular region of μOR and κOR, requiring Gi protein to open the cytoplasmic region by itself. We consider that this G protein-first mechanism may apply to activation of other Class A GPCRs. However, for δOR, agonist binding can open up the intracellular region to encourage Gi protein recruitment. Thus, activation of Gi protein mediated by δOR favourably may proceed with either ligand-first or G protein-first activation mechanisms.

Highlights

  • Chronic pain treatment is a major clinical challenge because most opioid analgesics such as morphine are associated with the side effects that hinder their application

  • We investigate the G protein-first paradigm (Fig. 1) using long-scale (~21 μs total) molecular dynamics (MD) simulations to follow the sequence of structural and energetic steps involved in activation of both the opioid receptors and the Gi protein

  • To obtain the structure for the human opioid receptors bound with the full Gi protein and agonists (Σ40), we started with the 3.5 Å resolution Cryo-electron microscopy (Cryo-EM) structure (Koehl et al, 2018) of mouse μOR bound to DAMGO and the nucleotide-free Gi protein

Read more

Summary

Introduction

Chronic pain treatment is a major clinical challenge because most opioid analgesics such as morphine are associated with the side effects that hinder their application. There is a great need to develop new pain therapeutics that attenuate the pain signals without the side effects. The primary target of morphine and other clinical opioid analgesics is the μ-opioid receptor, μOR (Pasternak and Pan, 2013), a G protein-coupled receptor (GPCR) that stimulates analgesic activity through signalling via the adenylyl cyclase-inhibitory family of G protein, Gi/o (Al-Hasani and Bruchas, 2011). To develop new analgesics with high efficacy but reduced side effects, it is critical to understand the activation mechanism underlying the choreography among μOR/κOR/δOR, Gi protein and agonists

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call